02/08/2020 / By Ethan Huff
As governments around the world scramble to contain novel coronavirus, which the World Health Organization (W.H.O.) has officially declared to be a “global emergency,” the vaccine industry is also rushing to create a jab for it. But the first one won’t be available for at least a year, according to Novartis CEO Vas Narasimhan – and will it even matter by then?
While early-stage trials for the first coronavirus vaccine could start within the next three months, it’ll take much longer than that to move the drug through the standard regulatory process. Even if it were to be fast-tracked, the vaccine would still take at least a year to hit the market – and by that point, novel coronavirus could already be a global pandemic with millions of infections.
Assuming this future coronavirus vaccine even works at all, it would probably be too little, too late. But Novartis and other drug companies are developing their own varieties of it regardless, presumably to keep the markets propped up amid this unfolding global crisis.
“It appears ‘trade optimism’ to save the stock market has turned to ‘coronavirus cure optimism,'” reports Zero Hedge about how the push to develop new coronavirus vaccines is an attempt at boosting vaccine industry stock values and investor optimism.
But is it working? Not necessarily. According to Zero Hedge, the Trump administration’s efforts to fast-track coronavirus vaccine development, as well as convey the message that all is under control, isn’t swaying investors to have a positive outlook on the situation. If anything, they’re becoming more concerned about major economic hiccups stemming from this outbreak.
“The reality is, it will take over a year in my expectation to really find a new vaccine for this, so we need to really use epidemiological controls to really get this situation in a better place,” Narasimhan is quoted as saying to CNBC‘s Julianna Tatelbaum.
As we know, vaccines in general are one of the greatest public health scams to ever be perpetrated on the masses regardless of how soon one for coronavirus hits the market. At best, it’ll provide artificial immunity against coronavirus that only lasts for a short period of time. At worst, it’ll actually cause more coronavirus, or perhaps provide temporary immunity against another type of it.
Both here and abroad, drug companies, scientists, and researchers are desperately trying to come up with a vaccine solution to coronavirus, but they’re all running into the same problem: It takes a very long time to get one to market, and by that point the virus will have already ravaged the planet.
Those on the ground in China are already saying that the battle against coronavirus has been lost. Mandatory quarantines and lockdowns don’t seem to be working, and increasingly more cases of coronavirus are turning up outside of China, which means there’s really not enough time to develop a vaccine.
“Buy some vitamin D,” wrote one Zero Hedge commenter, offering up a solution other than just chemical injections and N95 masks to protect oneself against coronavirus infection.
“I have killed every cold and flu for 20 years by taking a gram per hour until I feel well. A real killer virus may take 8 grams every 20 minutes for 4 hours. They make buffered C for those who cannot take regular C. Regular C is a little rough on the stomach.”
More up-to-the-minute news about coronavirus is available at Pandemic.news and Outbreak.news.
You can also investigate your own natural solutions that may help to protect you against coronavirus as well as the common cold and flu by visiting NaturalCures.news.
Sources for this article include:
Tagged Under: big pharma fails, China, coronavirus, global emergency, natural immunity, Novartis, outbreak, pandemic, Trump, vaccine, Vas Narasimhan, virus, Wuhan
Vaccines.News is a fact-based public education website published by Vaccines News Features, LLC.
All content copyright © 2018 by Vaccines News Features, LLC.
Contact Us with Tips or Corrections
All trademarks, registered trademarks and servicemarks mentioned on this site are the property of their respective owners.